Cargando…

Ovarian cancer

Detalles Bibliográficos
Autores principales:	Kerbrat, P, Lhommé, C, Fervers, B, Guastalla, J P, Thomas, L, Tournemaine, N, Basuyau, J P, Cohen-Solal, C, Duvillard, P, Bachelot, T, Ray, I, Voog, E, Dauplat, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408843/ https://www.ncbi.nlm.nih.gov/pubmed/11355964 http://dx.doi.org/10.1054/bjoc.2000.1758

Ejemplares similares

Carcinoma of the cervix
por: Resbeut, M, et al.
Publicado: (2001)

Cancer of the endometrium
por: Brémond, A, et al.
Publicado: (2001)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

The taxanes: toxicity and quality of life considerations in advanced ovarian cancer
por: Guastalla III, J P, et al.
Publicado: (2003)

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
por: Ray-Coquard, I, et al.
Publicado: (2001)

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2002)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma
por: Ito, I, et al.
Publicado: (2000)

Epithelial tumours of the thymus
por: Ruffié, P, et al.
Publicado: (2001)

Hodgkins disease
por: Ferme, C, et al.
Publicado: (2001)

Hormone replacement therapy and risk of epithelial ovarian cancer
por: Purdie, D M, et al.
Publicado: (1999)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Osteosarcoma
por: Philip, T, et al.
Publicado: (2001)

Morphological and Immunohistochemical Study of Ovarian and Tubal Dysplasia Associated with Tamoxifen
por: Chene, G., et al.
Publicado: (2014)

Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients
por: Hickey, K P, et al.
Publicado: (1999)

An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre
por: Sengupta, P S, et al.
Publicado: (1999)

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
por: McPhillips, F, et al.
Publicado: (2001)

SOR: project methodology
por: Fervers, B, et al.
Publicado: (2001)

Cutaneous melanoma
por: Négrier, S, et al.
Publicado: (2001)

Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines
por: Wilson, K E, et al.
Publicado: (1999)

Risk of ovarian cancer in relation to use of phenolphthalein-containing laxatives
por: Cooper, G S, et al.
Publicado: (2000)

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
por: Kerbrat, P, et al.
Publicado: (2007)

Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics
por: Engel, H, et al.
Publicado: (1999)

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families
por: Peelen, T, et al.
Publicado: (2000)

Expression of transcription factor AP-2α predicts survival in epithelial ovarian cancer
por: Anttila, M A, et al.
Publicado: (2000)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells
por: Dhar, K K, et al.
Publicado: (1999)

Effects of soy foods on ovarian function in premenopausal women
por: Wu, A H, et al.
Publicado: (2000)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy
por: Magnani, P, et al.
Publicado: (2000)

Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients
por: Taylor, D D, et al.
Publicado: (2001)

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
por: Beale, P J, et al.
Publicado: (2000)

Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868
por: Simpson, B J B, et al.
Publicado: (1999)

hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer
por: Ercoli, A, et al.
Publicado: (1999)

Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer
por: McDaid, H M, et al.
Publicado: (1999)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists
por: Chatzistamou, I, et al.
Publicado: (2000)

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer
por: Peters-Engl, C, et al.
Publicado: (1999)

A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
por: Vahteristo, P, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_f76j9509gbh6mcs4ce9e0vakd9